NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12.44 mln
Float1.39 mln
Earnings Date11/13/2026
Piotroski F-Score
5
/ 9
Neutral
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.13
Very low leverage
Pre-Tax Margin
-11,391%
Severely loss-making
ROE
-1,032
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Aspire Biopharma Holdings Inc. is a Florida-based biopharmaceutical company focused on developing medicines that dissolve under the tongue, allowing them to work faster than traditional pills. Its first product, Instaprin, is a pH-neutral sublingual aspirin designed for rapid relief in heart emergencies and pain management. The company is also working to bring the same delivery approach to a wide range of other products, including melatonin, vitamins, testosterone, semaglutide, anti-nausea and anti-psychotic drugs, seizure medications, and pre-workout supplements. Founded in 2021, Aspire aims to improve how common and critical medications are absorbed by the body.
